Management of MDR and rifampicin-resistant TB cases in Italy, 1995-1999
G. Ferrara, L. Richeldi, R. Centis, S. Nutini, M. Bugiani, F. Firentini, L. Casali, G. Besozzi, G. B. Migliori (Modena, Tradate, Italy)
Source: Annual Congress 2001 - Drug resistant TB
Session: Drug resistant TB
Session type: Oral Presentation
Number: 3463
Disease area: Respiratory infections
Abstract Surveillance data on drug resistance representative of the country are available in Italy since 1995 (SMIRA network, 30% of TB cases notified every year). Aim of the study is to evaluate the proportion of: 1. adequate regimens prescribed to MDR cases; 2. Regimens modified according to drug susceptibility testing (DST) in mono-rifampicin resistant cases. Methods: WHO recommendations were used, considering regimens adequate for MDR TB when at least 3 active drugs were prescribed. Data were stratified for Reference Units (>100 TB cases per year) and minor TB Units. Results: out of 4,316 TB cases notified by the network, 120 MDR and 47 rifampicin monoresistant cases were analysed. Regimens modified according to DST were prescribed in 73% of MDR TB cases. Reference Units managed 78 MDR and 6 rifampicin monoresistant cases, with a significantly higher proportion of adequate regimens than minor Units (92% vs 36%, p<0.0001). 30% of rifampicin-resistant TB cases were prescribed a regimen modified according to DST. In Reference Units the regimens were modified according to DST in a significantly higher proportion than in minor Units (83% vs 22%, p<0.0001). Conclusions: the majority of MDR cases are managed according to WHO guidelines, particularly in Reference Units.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Ferrara, L. Richeldi, R. Centis, S. Nutini, M. Bugiani, F. Firentini, L. Casali, G. Besozzi, G. B. Migliori (Modena, Tradate, Italy). Management of MDR and rifampicin-resistant TB cases in Italy, 1995-1999. Eur Respir J 2001; 16: Suppl. 31, 3463
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004 Source: Eur Respir J 2010; 36: 584-593 Year: 2010
MDR TB in Azerbaijan, 2006-2007 Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Treatment outcomes and deaths among multidrug-resistant tuberculosis (MDR-TB) patients in Gomel region, Belarus – 2009-2010 Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Treatment outcomes in patients with multidrug-resistant tuberculosis in Japan, 2011-2013 Source: International Congress 2017 – MDRTB: detection and management Year: 2017
Characteristics of XDR-TB patients in Israel: 2000-2010 Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011
Study of drug-resistant tuberculosis in Plovdiv region, Bulgaria - 1989-2003 Source: Eur Respir J 2005; 26: Suppl. 49, 651s Year: 2005
TB epidemiology and drug resistance in Bulgaria (1990-2003) Source: Eur Respir J 2004; 24: Suppl. 48, 199s Year: 2004
Predisposing factors of multi drug resistant tuberculosis (MDR-TB) in Sardjito Hospital, Yogyakarta, Indonesia in 2009-2012 Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014
High proportion of fluoroquinolone mono-resistant mycobacterium tuberculosis (MTB) strains in Pakistan (2010-2012) Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Our experience and treatment results of multidrug-resistant tuberculosis (MDR-TB) patients between 1996-2002 Source: Eur Respir J 2003; 22: Suppl. 45, 42s Year: 2003
Treatment outcomes of MDR-TB patients notified in Romania during 2005-2007 Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011
Treatment outcome in multidrug resistant tuberculosis cases at our clinic between 1996-2008 Source: Annual Congress 2009 - Multi/extensively-drug resistant tuberculosis Year: 2009
Multidrug–resistant tuberculosis in Czech Republic during the period of recent 5 years (2007-2012) Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management II Year: 2013
Multidrug resistant tuberculosis in previously treated and new cases registered between 2004-2008 in Romania Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
MDR and XDR-TB in Vojvodina province (Serbia) during 2000-2009 Source: Annual Congress 2010 - Various aspects of respiratory epidemiology Year: 2010
Epidemiology of tuberculosis (TB) in Poland in the period 1994-2003 Source: Eur Respir J 2005; 26: Suppl. 49, 191s Year: 2005
Drug resistance of mycobacterium tuberculosis isolates in Serbia over five-year period (2001-2005) Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis Year: 2008
Resistance to nosocomial pneumonia pathogens in 2005-2006 and in 2007 in Yaroslavl (Russia) Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010
Trends in tuberculosis in Romania between 2001-2006 Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis I Year: 2008
Resistance pattern of tuberculosis patients enrolled to Izmir esrefpasa tuberculosis dispensary between 1996-2001 Source: Eur Respir J 2002; 20: Suppl. 38, 615s Year: 2002